PARP Inhibitors: Synthetic Lethality in the Clinic

Overview

Journal Science

Specialty Science

Date 2017 Mar 18

PMID 28302823

Citations 1256

Authors

Christopher J Lord

Alan Ashworth

Affiliations

Soon will be listed here.

Abstract

PARP inhibitors (PARPi), a cancer therapy targeting poly(ADP-ribose) polymerase, are the first clinically approved drugs designed to exploit synthetic lethality, a genetic concept proposed nearly a century ago. Tumors arising in patients who carry germline mutations in either or are sensitive to PARPi because they have a specific type of DNA repair defect. PARPi also show promising activity in more common cancers that share this repair defect. However, as with other targeted therapies, resistance to PARPi arises in advanced disease. In addition, determining the optimal use of PARPi within drug combination approaches has been challenging. Nevertheless, the preclinical discovery of PARPi synthetic lethality and the route to clinical approval provide interesting lessons for the development of other therapies. Here, we discuss current knowledge of PARP inhibitors and potential ways to maximize their clinical effectiveness.

Citing Articles

Establishment and genomic profiling of cholangiocarcinoma cells with functional characterization.

Jaidee R, Jusakul A, Pocasap P, Kukongviriyapan V, Senggunprai L, Prawan A Sci Rep. 2025; 15(1):8621.

PMID: 40074934 PMC: 11904213. DOI: 10.1038/s41598-025-93192-1.

Predictive biomarkers for the efficacy of PARP inhibitors in ovarian cancer: an updated systematic review.

Wang Y, Allen I, Funingana G, Tischkowitz M, Joko-Fru Y BJC Rep. 2025; 3(1):14.

PMID: 40069561 PMC: 11897386. DOI: 10.1038/s44276-025-00122-9.

Olaparib increases chemosensitivity by upregulating miR-125a-3p in ovarian cancer cells.

Wang Z, Pu T, Miao W, Gao Y, Gao J, Zhang X Discov Oncol. 2025; 16(1):291.

PMID: 40064834 PMC: 11893969. DOI: 10.1007/s12672-025-02048-7.

Harnessing transcriptional regulation of alternative end-joining to predict cancer treatment.

Espin R, Medina-Jover F, Siguenza-Andrade J, Farran-Matas S, Mateo F, Figueras A NAR Cancer. 2025; 7(1):zcaf007.

PMID: 40061566 PMC: 11886861. DOI: 10.1093/narcan/zcaf007.

Hallmarks of artificial intelligence contributions to precision oncology.

Chang T, Park S, Schaffer A, Jiang P, Ruppin E Nat Cancer. 2025; .

PMID: 40055572 DOI: 10.1038/s43018-025-00917-2.

References

Barber L, Sandhu S, Chen L, Campbell J, Kozarewa I, Fenwick K . Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. J Pathol. 2012; 229(3):422-9. DOI: 10.1002/path.4140. View

Lord C, Ashworth A . Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med. 2013; 19(11):1381-8. DOI: 10.1038/nm.3369. View

Xu G, Chapman J, Brandsma I, Yuan J, Mistrik M, Bouwman P . REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature. 2015; 521(7553):541-544. PMC: 4671316. DOI: 10.1038/nature14328. View

Higuchi T, Flies D, Marjon N, Mantia-Smaldone G, Ronner L, Gimotty P . CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer. Cancer Immunol Res. 2015; 3(11):1257-68. PMC: 4984269. DOI: 10.1158/2326-6066.CIR-15-0044. View

Mukhopadhyay A, Elattar A, Cerbinskaite A, Wilkinson S, Drew Y, Kyle S . Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res. 2010; 16(8):2344-51. DOI: 10.1158/1078-0432.CCR-09-2758. View

Norquist B, Wurz K, Pennil C, Garcia R, Gross J, Sakai W . Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol. 2011; 29(22):3008-15. PMC: 3157963. DOI: 10.1200/JCO.2010.34.2980. View

Graeser M, McCarthy A, Lord C, Savage K, Hills M, Salter J . A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res. 2010; 16(24):6159-68. PMC: 3432445. DOI: 10.1158/1078-0432.CCR-10-1027. View

Murai J, Huang S, Das B, Renaud A, Zhang Y, Doroshow J . Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012; 72(21):5588-99. PMC: 3528345. DOI: 10.1158/0008-5472.CAN-12-2753. View

Ashworth A, Lord C, Reis-Filho J . Genetic interactions in cancer progression and treatment. Cell. 2011; 145(1):30-8. DOI: 10.1016/j.cell.2011.03.020. View

10.

Zaremba T, Curtin N . PARP inhibitor development for systemic cancer targeting. Anticancer Agents Med Chem. 2007; 7(5):515-23. DOI: 10.2174/187152007781668715. View

11.

Knezevic C, Wright G, Remsing Rix L, Kim W, Kuenzi B, Luo Y . Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets. Cell Chem Biol. 2016; 23(12):1490-1503. PMC: 5182133. DOI: 10.1016/j.chembiol.2016.10.011. View

12.

Campbell J, Ryan C, Brough R, Bajrami I, Pemberton H, Chong I . Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines. Cell Rep. 2016; 14(10):2490-501. PMC: 4802229. DOI: 10.1016/j.celrep.2016.02.023. View

13.

McCabe N, Turner N, Lord C, Kluzek K, Bialkowska A, Swift S . Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006; 66(16):8109-15. DOI: 10.1158/0008-5472.CAN-06-0140. View

14.

Pettitt S, Rehman F, Bajrami I, Brough R, Wallberg F, Kozarewa I . A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity. PLoS One. 2013; 8(4):e61520. PMC: 3636235. DOI: 10.1371/journal.pone.0061520. View

15.

Gonzalez Martin A . Progress in PARP inhibitors beyond BRCA mutant recurrent ovarian cancer?. Lancet Oncol. 2016; 18(1):8-9. DOI: 10.1016/S1470-2045(16)30621-0. View

16.

Bryant H, Schultz N, Thomas H, Parker K, Flower D, Lopez E . Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434(7035):913-7. DOI: 10.1038/nature03443. View

17.

Ibrahim Y, Garcia-Garcia C, Serra V, He L, Torres-Lockhart K, Prat A . PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2012; 2(11):1036-47. PMC: 5125254. DOI: 10.1158/2159-8290.CD-11-0348. View

18.

Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G . Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014; 15(8):852-61. DOI: 10.1016/S1470-2045(14)70228-1. View

19.

Isakoff S, Puhalla S, Domchek S, Friedlander M, Kaufman B, Robson M . A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncol. 2016; 13(4):307-320. PMC: 5618936. DOI: 10.2217/fon-2016-0412. View

20.

Fong P, Boss D, Yap T, Tutt A, Wu P, Mergui-Roelvink M . Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009; 361(2):123-34. DOI: 10.1056/NEJMoa0900212. View